Effect of Sequential Nephron Blockade versus Dual Renin-Angiotensin System Blockade Plus Bisoprolol in the Treatment of Resistant Hypertension, a Randomized Controlled Trial (Resistant Hypertension on Treatment - ResHypOT)
Authors:
- Elizabeth Do Espirito Santo CestarioECElizabeth Do Espirito Santo Cestario
- Jose Fernando Vilela-MartinJVJose Fernando Vilela-Martin
- Luciana Neves Cosenso-MartinLCLuciana Neves Cosenso-Martin
- Tatiane Azevedo RubioTRTatiane Azevedo Rubio
- Jessica Rodrigues Roma UyemuraJUJessica Rodrigues Roma Uyemura
- Valquiria da Silva LopesVLValquiria da Silva Lopes
- Letícia Aparecida Barufi FernandesLFLetícia Aparecida Barufi Fernandes
- Lucia Helena Bonalume TacitoLTLucia Helena Bonalume Tacito
- Heitor Moreno JuniorHJHeitor Moreno Junior
- Juan Carlos Yugar-ToledoJYJuan Carlos Yugar-Toledo
Open Access
- 15 December 2022
- journal article
- research article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 18, 867-878
Abstract
Introduction: Hypertension is the most important modifiable risk factor for cardiovascular disease and a leading public health concern. Objectives: The primary aim was to compare sequential nephron blockade (SNB) versus dual renin-angiotensin system blockade (DRASB) plus bisoprolol in patients with resistant hypertension to observe reductions in systolic and diastolic blood pressure (SBP and DBP) levels after 20 weeks of treatment. Material and Methods: This trial was an open-label, prospective, randomized, parallel-group, clinical study with optional drug up-titration. Participants were evaluated during five visits at 28-day intervals. Results: The mean age was 55.5 years in the SNB and 58.4 years in the DRASB + bisoprolol group (p=NS). Significant office BP reductions were observed in both groups. SNB group, SBP decreased from 174.5± 21.0 to 127.0± 14.74 mmHg (p< 0.0001), and DBP decreased from 105.3± 15.5 to 78.11± 9.28 mmHg (p< 0.0001). DRASB group, SBP decreased from 178.4± 21.08 to 134.4 ± 23.25 mmHg (p< 0.0001) and DBP decreased from 102.7± 11.07 to 77.33± 13.75 mmHg (p< 0.0001). Ambulatory blood pressure monitoring (ABPM) showed also significant SBP and DBP reductions in both groups (p< 0.0001). Conclusion: In patients with RHTN adherent to treatment, SNB and DRASB plus bisoprolol showed excellent therapeutic efficacy, although SNB was associated with earlier SBP reduction.Keywords
This publication has 41 references indexed in Scilit:
- Incidence and Prognosis of Resistant Hypertension in Hypertensive PatientsCirculation, 2012
- Pathophysiology of Resistant Hypertension: The Role of Sympathetic Nervous SystemInternational Journal of Hypertension, 2011
- Efficacy of Spironolactone Therapy in Patients With True Resistant HypertensionHypertension, 2010
- Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic NephropathyJournal of the American Society of Nephrology, 2009
- Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant HypertensionHypertension, 2009
- Intensive Monitoring of Adherence to Treatment Helps to Identify “True” Resistant HypertensionThe Journal of Clinical Hypertension, 2009
- Resistant Hypertension: Diagnosis, Evaluation, and TreatmentHypertension, 2008
- Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trialKidney International, 2007
- Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in HypertensionHypertension, 2005
- Resistant HypertensionHypertension, 2002